<sentence id="0">The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1 .</sentence>
<sentence id="1">This study demonstrates deregulation of polycomb activity by the synovial sarcoma-associated SYT-SSX2 oncogene , also known as SS18-SSX2 .</sentence>
<sentence id="2">Synovial sarcoma is a soft tissue cancer associated with a recurrent t(X:18) translocation event that generates one of two fusion proteins , SYT-SSX1 or SYT-SSX2 .</sentence>
<sentence id="3">The role of the translocation products in this disease is poorly understood .</sentence>
<sentence id="4">We present evidence that the SYT-SSX2 fusion protein interacts with the polycomb repressive complex and modulates its gene silencing activity .</sentence>
<sentence id="5">SYT-SSX2 causes destabilization of the polycomb subunit Bmi1 , resulting in impairment of polycomb-associated histone H2A ubiquitination and reactivation of polycomb target genes .</sentence>
<sentence id="6">Silencing by polycomb complexes plays a vital role in numerous physiological processes .</sentence>
<sentence id="7">In recent years , numerous reports have implicated gain of polycomb silencing function in several cancers .</sentence>
<sentence id="8">This study provides evidence that , in the appropriate context , expression of the SYT-SSX2 oncogene leads to loss of polycomb function .</sentence>
<sentence id="9">It challenges the <scope type="spec" id="0"> <cue type="spec" id="0">notion</cue> that cancer is solely associated with an increase in polycomb function</scope> and <scope type="spec" id="1"> <cue type="spec" id="1">suggests</cue> that any imbalance in polycomb activity <scope type="spec" id="2"> <cue type="spec" id="2">could</cue> drive the cell toward oncogenesis</scope></scope> .</sentence>
<sentence id="10">These findings provide a mechanism by which the SYT-SSX2 chimera <scope type="spec" id="3"> <cue type="spec" id="3">may</cue> contribute to synovial sarcoma pathogenesis</scope> .</sentence>